{"id":"W2803073301","doi":"10.1016/j.jid.2018.03.395","title":"388 A phase Ib trial in AD patients evaluating safety, tolerability, pharmacokinetics and efficacy of topical formulations containing the kappa-opioid receptor agonist WOL071-007","year":2018,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals; Therakos","keywords":"Tolerability; Medicine; Placebo; Pharmacology; Pharmacokinetics; Agonist; Atopic dermatitis; SCORAD; κ-opioid receptor; Psoriasis; Internal medicine; Adverse effect; Dermatology; Receptor; Pathology; Dermatology Life Quality Index","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005907259,0.001197722,0.001452816,0.0002925659,0.0003454547,0.0006260999,0.0006412089,0.0009691885,0.009230705],"category_scores_gemma":[0.0005413564,0.0004173333,0.001095369,0.0002291254,0.0006123424,0.0007027468,0.0002300235,0.00243147,0.001891803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005915865,"about_ca_system_score_gemma":0.0009329945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001056745,"about_ca_topic_score_gemma":0.002120718,"domain_scores_codex":[0.9997638,0.00009156105,0.00001353882,0.00004340305,0.0000238662,0.00006387086],"domain_scores_gemma":[0.9997379,0.00006067256,0.00003526826,0.00002326637,0.00002583083,0.0001169612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6931266,0.04798177,0.002891848,0.001015215,0.00130722,0.0003006413,0.0002548199,0.001765102,0.07106681,0.0006813675,0.005587335,0.1740212],"study_design_scores_gemma":[0.5483237,0.4315035,0.005727501,0.00007424721,0.0004517164,0.0003718252,0.0001128579,0.001855067,0.005277838,0.0006448787,0.005602445,0.00005439102],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989274,0.002183862,0.0005510958,0.0004647658,0.000116469,0.001608841,0.001425993,0.0001126707,0.004262211],"genre_scores_gemma":[0.9799393,0.002805007,0.002362646,0.0008820571,0.0001302626,0.002089619,0.003087688,0.00004621516,0.008657088],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009230705,"threshold_uncertainty_score":0.0308798,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05644523199739024,"score_gpt":0.3871413165467615,"score_spread":0.3306960845493713,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}